▲ +338.71% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $20.40, with a high forecast of $45.00 and a low forecast of $6.00. The average price target represents a 338.71% upside from the last price of $4.65.
The current consensus among 6 polled investment analysts is to hold stock in Aprea Therapeutics.
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.